青青草a国产免费观看|91麻豆精品国产福利|国产av五无码一级毛片|亚洲爆乳精品无码一区二区|久久亚洲AV成人无码国产|91无码人妻一区二区三区|色婷婷av一区二区三区性色|国产制服91一区二区三区制服,女人书籍排行榜,盗墓笔记小说txt下载,玄幻小说排行榜完本

position: EnglishChannel  > News> Tech-Finance Synergy Unlocks Innovation Potential

Tech-Finance Synergy Unlocks Innovation Potential

Source: Science and Technology Daily | 2025-07-01 18:22:28 | Author: LI Linxu

Thanks to strong policy support, a favorable market environment and a sound innovation ecosystem, the virtuous cycle of tech, capital and industry is gaining greater momentum in China.

While global IPO markets stagnate in year-to-date 2025 — with listings down 11 percent by volume worldwide, the Chinese mainland's A-share market and the Hong Kong exchanges have emerged as twin engines of growth.

Recent EY data reveals the Hong Kong exchanges' staggering 711 percent year-on-year fundraising leap in the first half of 2025, capturing 24 percent of global IPO capital, while the A-share market posted double digit growth in both deal volume and value.

By sector, the industrial, technology, and materials sectors took the top three spots in both IPO volume and fundraising amount in the A-share market. Notably, among the IPOs listed in the first half of 2025 in the A-share market, more than 30 percent of companies belonged to upstream and downstream enterprises in the automotive industry.

As EY Greater China IPO Leader Terence Ho noted, the technology attribute of the A-share market is becoming increasingly prominent, with capital markets rapidly converging towards sci-tech enterprises. Domestic industrial upgrading has driven increased listing and financing needs of sci-tech innovation companies. Premium sci-tech enterprises that meet listing requirements are expected to be prioritized in the pipeline, aligning more precisely with the real economy's demand for high-quality development.

Meanwhile, the China Securities Regulatory Commission (CSRC) has repeatedly emphasized stronger support for high-quality yet unprofitable tech companies to list, indicating that institutional dividends for sci-tech innovation firms are expected to materialize at a faster pace and the listing and financing environment will continue to optimize.

This is underscored by CSRC Chairman Wu Qing's pledge at the recent Lujiazui Forum in Shanghai to "empower the integration of tech and industrial innovation through deepening the opening up and reform of capital market."

Statistics show that listed enterprises have emerged as a core engine of sci-tech innovation. In 2024, the R&D expenditure of A-share listed entities reached 1.88 trillion RMB, accounting for more than 50 percent of national R&D investment.

The innovation trajectory—ignited by technology, scaled by industry, and monetized through capital—has become increasingly evident.

The EY report projects that in the second half of 2025, A-share IPO activities will intensify focus on the sci-tech innovation sector. The listing prospects for sci-tech innovation enterprises remain promising.

As the path forward requires deeper integration of financial infrastructure with innovation ecosystems, tech-finance synergy is no longer optional — it's the cornerstone of competitive economies.

Editor:李林旭

Top News

Jointly Protecting People's Rights in Digital Era

?Emerging technologies like AI, big data and the Internet of Things are rapidly reshaping the world in this era of digital intelligence. However, they are also bringing challenges to human rights, which makes joint efforts essential. Science and Technology Daily spoke with international experts on these issues against the backdrop of the 2025 China-Europe Seminar on Human Rights hosted by the China Society for Human Rights Studies and Cátedra China Foundation in Madrid, Spain, on June 25 on the theme "Human Rights in the Era of Digital Intelligence."

First Human Clinical Trial of Invasive BCI in China

A major breakthrough in neurotechnology has been achieved with the successful completion of China's first-in-human clinical trial of an invasive brain-computer interface (BCI) system. With that China becomes the second country in the world to reach the clinical stage in this field.

抱歉,您使用的瀏覽器版本過低或開啟了瀏覽器兼容模式,這會影響您正常瀏覽本網(wǎng)頁

您可以進(jìn)行以下操作:

1.將瀏覽器切換回極速模式

2.點擊下面圖標(biāo)升級或更換您的瀏覽器

3.暫不升級,繼續(xù)瀏覽

繼續(xù)瀏覽
丹东市| 金溪县| 淅川县| 全州县| 奉化市| 民县| 柯坪县| 漾濞| 十堰市| 乐平市| 冀州市| 平乐县| 裕民县| 浪卡子县| 沂源县| 祁门县| 陇川县| 龙海市| 肇东市| 香格里拉县| 界首市| 射洪县| 津市市| 保山市| 梨树县| 嘉黎县| 洛隆县| 合川市| 宣城市| 平罗县| 梅州市| 上杭县| 句容市| 丘北县| 涟源市| 满洲里市| 洞口县| 马公市| 博白县| 长宁区| 龙海市|